| Tbio | Interferon-induced GTP-binding protein Mx2 |
Interferon-induced dynamin-like GTPase with potent antiviral activity against human immunodeficiency virus type 1 (HIV-1). Acts by targeting the viral capsid and affects the nuclear uptake and/or stability of the HIV-1 replication complex and the subsequent chromosomal integration of the proviral DNA. Exhibits antiviral activity also against simian immunodeficiency virus (SIV-mnd). May play a role in regulating nucleocytoplasmic transport and cell-cycle progression.
The protein encoded by this gene has a nuclear and a cytoplasmic form and is a member of both the dynamin family and the family of large GTPases. The nuclear form is localized in a granular pattern in the heterochromatin region beneath the nuclear envelope. A nuclear localization signal (NLS) is present at the amino terminal end of the nuclear form but is lacking in the cytoplasmic form due to use of an alternate translation start codon. This protein is upregulated by interferon-alpha but does not contain the antiviral activity of a similar myxovirus resistance protein 1. [provided by RefSeq, Jul 2008]
The protein encoded by this gene has a nuclear and a cytoplasmic form and is a member of both the dynamin family and the family of large GTPases. The nuclear form is localized in a granular pattern in the heterochromatin region beneath the nuclear envelope. A nuclear localization signal (NLS) is present at the amino terminal end of the nuclear form but is lacking in the cytoplasmic form due to use of an alternate translation start codon. This protein is upregulated by interferon-alpha but does not contain the antiviral activity of a similar myxovirus resistance protein 1. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Influenza, Human | 51 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| juvenile dermatomyositis | 1187 | 3.0e-21 |
| lung carcinoma | 2843 | 3.3e-13 |
| malignant mesothelioma | 3232 | 7.0e-09 |
| cutaneous lupus erythematosus | 1057 | 2.7e-06 |
| Breast cancer | 3578 | 1.9e-05 |
| pancreatic cancer | 2398 | 5.1e-05 |
| ulcerative colitis | 1819 | 5.3e-05 |
| psoriasis | 6694 | 6.6e-05 |
| intraductal papillary-mucinous neoplasm (IPMN) | 3291 | 2.9e-04 |
| ovarian cancer | 8520 | 3.6e-04 |
| interstitial cystitis | 2312 | 4.2e-04 |
| subependymal giant cell astrocytoma | 2287 | 1.2e-03 |
| lung cancer | 4740 | 1.5e-03 |
| group 3 medulloblastoma | 4104 | 3.1e-03 |
| cystic fibrosis | 1696 | 4.5e-03 |
| Multiple Sclerosis | 540 | 7.6e-03 |
| dermatomyositis | 966 | 1.2e-02 |
| intraductal papillary-mucinous adenoma (IPMA) | 2955 | 2.8e-02 |
| intraductal papillary-mucinous carcinoma (IPMC) | 2989 | 4.1e-02 |
| Disease | log2 FC | p |
|---|---|---|
| Breast cancer | 1.400 | 1.9e-05 |
| cutaneous lupus erythematosus | 3.600 | 2.7e-06 |
| cystic fibrosis | 1.483 | 4.5e-03 |
| dermatomyositis | 1.400 | 1.2e-02 |
| group 3 medulloblastoma | -1.100 | 3.1e-03 |
| interstitial cystitis | 1.600 | 4.2e-04 |
| intraductal papillary-mucinous adenoma (... | 1.300 | 2.8e-02 |
| intraductal papillary-mucinous carcinoma... | 1.300 | 4.1e-02 |
| intraductal papillary-mucinous neoplasm ... | 2.900 | 2.9e-04 |
| juvenile dermatomyositis | 2.495 | 3.0e-21 |
| lung cancer | -1.300 | 1.5e-03 |
| lung carcinoma | -2.200 | 3.3e-13 |
| malignant mesothelioma | 3.800 | 7.0e-09 |
| Multiple Sclerosis | 1.700 | 7.6e-03 |
| ovarian cancer | 2.300 | 3.6e-04 |
| pancreatic cancer | 1.300 | 5.1e-05 |
| psoriasis | 1.300 | 6.6e-05 |
| subependymal giant cell astrocytoma | 1.889 | 1.2e-03 |
| ulcerative colitis | 2.000 | 5.3e-05 |
| Species | Source | Disease |
|---|---|---|
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG |
MSKAHKPWPYRRRSQFSSRKYLKKEMNSFQQQPPPFGTVPPQMMFPPNWQGAEKDAAFLAKDFNFLTLNN 1 - 70 QPPPGNRSQPRAMGPENNLYSQYEQKVRPCIDLIDSLRALGVEQDLALPAIAVIGDQSSGKSSVLEALSG 71 - 140 VALPRGSGIVTRCPLVLKLKKQPCEAWAGRISYRNTELELQDPGQVEKEIHKAQNVMAGNGRGISHELIS 141 - 210 LEITSPEVPDLTIIDLPGITRVAVDNQPRDIGLQIKALIKKYIQRQQTINLVVVPCNVDIATTEALSMAH 211 - 280 EVDPEGDRTIGILTKPDLMDRGTEKSVMNVVRNLTYPLKKGYMIVKCRGQQEITNRLSLAEATKKEITFF 281 - 350 QTHPYFRVLLEEGSATVPRLAERLTTELIMHIQKSLPLLEGQIRESHQKATEELRRCGADIPSQEADKMF 351 - 420 FLIEKIKMFNQDIEKLVEGEEVVRENETRLYNKIREDFKNWVGILATNTQKVKNIIHEEVEKYEKQYRGK 421 - 490 ELLGFVNYKTFEIIVHQYIQQLVEPALSMLQKAMEIIQQAFINVAKKHFGEFFNLNQTVQSTIEDIKVKH 491 - 560 TAKAENMIQLQFRMEQMVFCQDQIYSVVLKKVREEIFNPLGTPSQNMKLNSHFPSNESSVSSFTEIGIHL 561 - 630 NAYFLETSKRLANQIPFIIQYFMLRENGDSLQKAMMQILQEKNRYSWLLQEQSETATKRRILKERIYRLT 631 - 700 QARHALCQFSSKEIH 701 - 715 //
